Panna Sanga

Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain

Panna Sanga, Nathaniel P. Katz, Elena Polverejan et al. · Pain · 2013 · 105 citations

Pain Therapy, Osteoarthritis Pain, Pain Disorders +15

Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease

Reisa A. Sperling, David Henley, Paul Aisen et al. · JAMA Neurology · 2021 · 101 citations · Full text

<p>Patients’ Preference for Long-Acting Injectable versus Oral Antipsychotics in Schizophrenia: Results from the Patient-Reported Medication Preference Questionnaire</p>

Clifton Blackwood, Panna Sanga, Isaac Nuamah et al. · Patient Preference and Adherence · 2020 · 62 citations · Full text

A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia

Dean Najarian, Panna Sanga, Steven Wang et al. · The International Journal of Neuropsychopharmacology · 2021 · 57 citations · Full text

Fulranumab for treatment of diabetic peripheral neuropathic pain

Hao Wang, Gary Romano, Mary Ellen Frustaci et al. · Neurology · 2014 · 46 citations · Full text